These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284 [TBL] [Abstract][Full Text] [Related]
5. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations. Tornøe CW; Overgaard RV; Agersø H; Nielsen HA; Madsen H; Jonsson EN Pharm Res; 2005 Aug; 22(8):1247-58. PubMed ID: 16078134 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN Pharm Res; 2004 Apr; 21(4):574-84. PubMed ID: 15139513 [TBL] [Abstract][Full Text] [Related]
7. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Steinberg M Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. Tornøe CW; Agersø H; Senderovitz T; Nielsen HA; Madsen H; Karlsson MO; Jonsson EN Br J Clin Pharmacol; 2007 Jun; 63(6):648-64. PubMed ID: 17096678 [TBL] [Abstract][Full Text] [Related]
9. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699 [TBL] [Abstract][Full Text] [Related]
11. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. Bauer RJ; Guzy S; Ng C AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237 [TBL] [Abstract][Full Text] [Related]
13. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469 [TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone antagonist: A real advantage? Kimura T; Sasaki H; Akazawa K; Egawa S Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of uncertainty parameters estimated by different population PK software and methods. Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368 [TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: Degarelix--a potential new therapy for prostate cancer. Doehn C; Sommerauer M; Jocham D IDrugs; 2006 Aug; 9(8):565-72. PubMed ID: 16871466 [TBL] [Abstract][Full Text] [Related]
17. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Anderson J Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172 [TBL] [Abstract][Full Text] [Related]
18. Degarelix acetate for the treatment of prostate cancer. Klotz L Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136 [TBL] [Abstract][Full Text] [Related]
19. Performance of different population pharmacokinetic algorithms. Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327 [TBL] [Abstract][Full Text] [Related]
20. An implementation of the Expectation-Maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME. Yates JW Comput Methods Programs Biomed; 2009 Oct; 96(1):49-62. PubMed ID: 19410328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]